1.Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy
Seungyong SHIN ; Pyunghwajun LEE ; Jieun HAN ; Se-Na KIM ; Jaesung LIM ; Dae-Hwan PARK ; Taejong PAIK ; Junhong MIN ; Chun Gwon PARK ; Wooram PARK
Tissue Engineering and Regenerative Medicine 2023;20(3):371-387
Adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells (CAR-Ts) has emerged as an innovative immunotherapy for hematological cancer treatment. However, the limited effect on solid tumors, complex processes, and excessive manufacturing costs remain as limitations of CAR-T therapy. Nanotechnology provides an alternative to the conventional CAR-T therapy. Owing to their unique physicochemical properties, nanoparticles can not only serve as a delivery platform for drugs but also target specific cells. Nanoparticle-based CAR therapy can be applied not only to T cells but also to CAR-natural killer and CAR-macrophage, compensating for some of their limitations. This review focuses on the introduction of nanoparticle-based advanced CAR immune cell therapy and future perspectives on immune cell reprogramming.
Result Analysis
Print
Save
E-mail